Skip to main content

Table 1 Characteristics, laboratory data, and treatments of SLE patients with and without LN

From: Identification of monoclonal antibodies against human renal glomerular endothelial cells in lupus nephritis that induce endothelial interferon-alpha production

  LN patients (N = 12) SLE patients without LN (N = 12)
Female: male 10:2 11:1
Age in years 17.34 (11–27) 17.93 (12–27.8)
Laboratory data
 ANA (+) 12 (100%) 12 (100%)
 Anti-dsDNA Ab (+) 12 (100%) 12 (100%)
 Anti-dsDNA Ab level (IU/ml)* 790.04 ± 257.39 508.25 ± 277.07
 DRVVT and/or IgG/IgM anticardiolipin Ab (+) 4 (33.3%) 3 (25%)
 WBC count (× 103/ml) 6292.20 ± 4097.73 5632.50 ± 2435.47
 Hemoglobin (g/dl)** 9.63 ± 1.92 11.9 ± 1.36
 Platelet count (× 103/ml) 210.00 ± 99.10 220.17 ± 96.94
 C3 (mg/ml)** 40.67 ± 18.45 76.16 ± 18.79
 C4 (mg/ml)** 7.41 ± 3.78 13.52 ± 5.35
Treatments (ever used)
 Corticosteroid 12 (100%) 12 (100%)
 MP pulse therapy** 11 (91.7%) 3 (25%)
 CTX pulse therapy** 9 (75%) 1 ( 8.33%)
 HCQ 12 (100%) 12 (100%)
 AZA 5 (41.7%) 6 (50%)
 CsA 7 (58.3%) 6 (50%)
 MTX 3 (25%) 2 (16.7%)
 MMF 5 (41.7%) 4 (33.3%)
  1. ANA antinuclear antibodies, Ab antibodies, DRVVT dilute Russell viper venom time, C complement, MP methylprednisolone, CTX cyclophosphamide, HCQ hydroxychloroquine, AZA azathioprine, CsA cyclosporine A, MTX methotrexate, MMF mycophenolate mofetil
  2. *Significant difference (p < 0.05) between LN patients and SLE patients without LN
  3. **Significant difference (p < 0.001) between LN patients and SLE patients without LN